Breaking News Instant updates and real-time market news.

VKTX

Viking Therapeutics

$11.15

0.91 (8.89%)

, MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

07:44
06/14/18
06/14
07:44
06/14/18
07:44

H.C. Wainwright says don't forget about Viking with Madrigal in play

After Bloomberg reported that Madrigal Pharmaceuticals (MDGL) is exploring a sale after receiving takeover interest, H.C. Wainwright analyst Joseph Pantginis tells investors to not forget about Viking Therapeutics (VKTX). The latter's potential treatment for non-alcoholic steatohepatitis, VK2809, could be even better than Madrigal's, Pantginis contends. The analyst believes that with Madrigal in play, it continues to bring "deserved focus to VK2809, which should garner significant business development interest as well." The analyst thinks VK2809 is "just starting to realize its underlying value from an investment standpoint." Citing the market potential for VK2809 and VK5211, the analyst highlights the value disconnect when comparing Madrigal's market capitalization of $4.8B with Viking's at $652M. Pantginis keeps a Buy rating on Viking Therapeutics with a $15 price target.

VKTX

Viking Therapeutics

$11.15

0.91 (8.89%)

MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

VKTX Viking Therapeutics
$11.15

0.91 (8.89%)

06/01/18
HCWC
06/01/18
NO CHANGE
Target $15
HCWC
Buy
Viking Therapeutics price target raised to $15 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Viking Therapeutics (VKTX) to $15 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) validate the thyroid receptor beta approach and derisks the VK2809 Phase 2 outcome. The analyst keeps a Buy rating on shares of Viking Therapeutics.
06/01/18
MAXM
06/01/18
NO CHANGE
Target $14
MAXM
Buy
Viking Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised his price target for Viking Therapeutics (VKTX) to $14 from $8 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) suggests that this class of Thyroid Hormone Receptor Beta agonist may be a successful treatment for NASH and that Viking's VK2809 could have similar success.
06/01/18
ROTH
06/01/18
NO CHANGE
Target $13
ROTH
Buy
Viking Therapeutics price target raised to $13 from $7.50 at Roth Capital
Roth Capital analyst Scott Henry maintained a Buy rating on Viking Therapeutics while raising his price target to $13 from $7.50 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) appears to validate the class of Thyroid Hormone Receptor Beta agonist compounds, noting that Viking's VK2809 is a similar agonist. In a research note to investors, Henry said he assumes that enrollment for VK2809 in a Phase 2 trial to treat NAFLD/hypercholesterolemia will be completed this month with a data readout in about October, and, assuming the readout is positive, Viking will meet with the FDA to determine the next steps. Henry believes the company may look to move directly to a phase 2/3 sequential trial.
06/05/18
MAXM
06/05/18
NO CHANGE
Target $14
MAXM
Buy
Chances of beta agonist success favors Viking Therapeutics, says Maxim
After Viking Therapeutics (VKTX) announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, Maxim analyst Jason McCarthy said that given Viking's prior data and the data for Madrigal's (MDGL) MGL-3196, which is in the same class of Thyroid Hormone Receptor beta agonists, that he believes the probability of success favors Viking. He maintains a Buy rating and $14 price target on Viking shares.
MDGL Madrigal Pharmaceuticals
$313.25

31.25 (11.08%)

06/07/18
EVER
06/07/18
NO CHANGE
Target $300
EVER
Outperform
Evercore ISI 'comfortable' with $300 price target on Madrigal after secondary
Evercore ISI analyst Josh Schimmer said he remains "comfortable" with his $300 price target on Madrigal Pharmaceuticals despite the stock trading off following the company's secondary offering of stock. After fielding calls from investors, Schimmer thinks a lack of catalysts "is probably the number one concern," as the company hopes to be able to start a Phase 3 NASH trial by year-end, which "probably means a 2-3 year void of news flow." Schimmer also listed long-term safety and efficacy and competitive dynamics as concerns voiced by investors he spoke with. He maintains an Outperform rating on Madrigal, which dropped over 10% in today's trading to about $281 per share.
06/12/18
MAXM
06/12/18
NO CHANGE
Target $30
MAXM
Buy
Galmed price target raised to $30 from $14 at Maxim
Maxim analyst Jason McCarthy raised his outyear estimates for Aramchol and reduced his risk adjustment to 15% from 30% following the announcement of Galmed's (GLMD) Phase 2b data for Aramchol in NASH. Given the changes, he raised his price target on Galmed shares to $30 from $14, which he notes implies a market capitalization of $450M. That valuation may be viewed as "conservative" given the rise in valuations of others in the NASH space, including Madrigal (MDGL), which McCarthy said completed a Phase 2 study that was "smaller and shorter" than Galmed. He maintains a Buy rating on Galmed shares, which are up $13, or 185% to about $20 per share in afternoon trading.

TODAY'S FREE FLY STORIES

VSAT

ViaSat

$65.44

-0.01 (-0.02%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
ViaSat announces agreement with Sandler Partners »

Viasat announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

MYE

Myers Industries

$15.83

-0.41 (-2.52%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
Myers Industries promotes Kevin Brackman to CFO »

Myers Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ASB

Associated Banc-Corp

$21.23

-0.4 (-1.85%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
Associated Banc-Corp subsidiary to acquire branch of Huntington Bancshares »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$47.00

0.61 (1.31%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Hot Stocks
Trinseo CEO Chris Pappas to retire in 2019 »

Trinseo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$98.46

-1.11 (-1.11%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Hot Stocks
Equifax awarded utility patent for innovative NeuroDecision Technology »

Equifax has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Recommendations
Stitch Fix analyst commentary  »

Stitch Fix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$86.34

-0.55 (-0.63%)

07:59
12/11/18
12/11
07:59
12/11/18
07:59
Conference/Events
LogMeln management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

FTSI

FTS International

$7.36

-0.41 (-5.28%)

07:59
12/11/18
12/11
07:59
12/11/18
07:59
Upgrade
FTS International rating change  »

FTS International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$37.70

0.7 (1.89%)

07:58
12/11/18
12/11
07:58
12/11/18
07:58
Hot Stocks
Urban Outfitters says retail comps up mid single-digit thus far in Q4 »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.94

-0.04 (-1.34%)

07:56
12/11/18
12/11
07:56
12/11/18
07:56
Conference/Events
LendingClub management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HP

Helmerich & Payne

$59.22

-1.54 (-2.53%)

07:56
12/11/18
12/11
07:56
12/11/18
07:56
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Recommendations
Stitch Fix analyst commentary  »

Stitch Fix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVTY

Tivity Health

$27.66

-12.94 (-31.87%)

, NTRI

Nutrisystem

$43.68

9.49 (27.76%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Recommendations
Tivity Health, Nutrisystem analyst commentary  »

Tivity Health price…

TVTY

Tivity Health

$27.66

-12.94 (-31.87%)

NTRI

Nutrisystem

$43.68

9.49 (27.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Initiation
Roche initiated  »

Roche assumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

  • 24

    Dec

  • 18

    Mar

07:55
12/11/18
12/11
07:55
12/11/18
07:55
General news
U.S. chain store sales rebounded 2.1% in the week ended December 8 »

U.S. chain store sales…

AJG

Arthur J. Gallagher

$74.58

-0.03 (-0.04%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
Arthur J. Gallagher to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BLRX

BioLineRx

$0.66

0.005 (0.76%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
BioLineRx to host investor meeting »

Investor Breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

THS

TreeHouse

$48.95

-1.22 (-2.43%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
TreeHouse to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

NVO

Novo Nordisk

$45.97

0.59 (1.30%)

07:54
12/11/18
12/11
07:54
12/11/18
07:54
Initiation
Novo Nordisk initiated  »

Novo Nordisk assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$86.94

-0.22 (-0.25%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Initiation
Novartis initiated  »

Novartis assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$145.31

-0.07 (-0.05%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Conference/Events
Johnson & Johnson management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

WFT

Weatherford

$0.46

-0.0579 (-11.21%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Downgrade
Weatherford rating change  »

Weatherford downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$37.68

0.4 (1.07%)

07:52
12/11/18
12/11
07:52
12/11/18
07:52
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$38.41

0.23 (0.60%)

07:52
12/11/18
12/11
07:52
12/11/18
07:52
Initiation
AstraZeneca initiated  »

AstraZeneca assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$25.04

3.59 (16.74%)

07:50
12/11/18
12/11
07:50
12/11/18
07:50
Hot Stocks
Kiniksa announces interim data of rilonacept trial, initiates RHAPSODY trial »

Kiniksa announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.